ES2909350T3 - Composiciones de ésteres de ácido cannabidiólico y usos de las mismas - Google Patents

Composiciones de ésteres de ácido cannabidiólico y usos de las mismas Download PDF

Info

Publication number
ES2909350T3
ES2909350T3 ES18739958T ES18739958T ES2909350T3 ES 2909350 T3 ES2909350 T3 ES 2909350T3 ES 18739958 T ES18739958 T ES 18739958T ES 18739958 T ES18739958 T ES 18739958T ES 2909350 T3 ES2909350 T3 ES 2909350T3
Authority
ES
Spain
Prior art keywords
branched
straight
disease
compound
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18739958T
Other languages
English (en)
Spanish (es)
Inventor
Raphael Mechoulam
Linda Parker
Roger Pertwee
Aron Weller
Joseph Tam
Christeen Haj
Reem Smoum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Guelph
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
University of Guelph
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Guelph, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical University of Guelph
Application granted granted Critical
Publication of ES2909350T3 publication Critical patent/ES2909350T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES18739958T 2017-06-20 2018-06-20 Composiciones de ésteres de ácido cannabidiólico y usos de las mismas Active ES2909350T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762522243P 2017-06-20 2017-06-20
PCT/IL2018/050678 WO2018235079A1 (en) 2017-06-20 2018-06-20 CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF

Publications (1)

Publication Number Publication Date
ES2909350T3 true ES2909350T3 (es) 2022-05-06

Family

ID=62875079

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18739958T Active ES2909350T3 (es) 2017-06-20 2018-06-20 Composiciones de ésteres de ácido cannabidiólico y usos de las mismas

Country Status (12)

Country Link
US (1) US11440870B2 (https=)
EP (1) EP3509638B1 (https=)
JP (1) JP2020524679A (https=)
CN (2) CN121534035A (https=)
AU (1) AU2018287018B2 (https=)
BR (1) BR112019026916A2 (https=)
CA (1) CA3067512A1 (https=)
DK (1) DK3509638T3 (https=)
ES (1) ES2909350T3 (https=)
MX (1) MX389847B (https=)
PT (1) PT3509638T (https=)
WO (1) WO2018235079A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
PT3509638T (pt) 2017-06-20 2022-03-02 Univ Guelph Composições de ésteres de ácido canabidiólico e suas utilizações
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20220054380A1 (en) * 2018-12-25 2022-02-24 Epm (Ip), Inc. Cannabidioloic acid esters for cosmetic or edible compositions
KR20210151816A (ko) * 2019-03-12 2021-12-14 이피엠 (아이피), 인코포레이티드 칸나비노이드 산 에스테르 조성물 및 이의 용도
JP2022545491A (ja) 2019-08-22 2022-10-27 イーピーエム（アイピー）， インコーポレイテッド カンナビノイド酸エステル組成物およびその使用
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
IL275108A (en) * 2020-06-03 2022-01-01 Epm Ip Inc Abnormal acid cannabidiol (abn-cbd) derivatives and their uses
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
IL303739A (en) * 2020-12-24 2023-08-01 Buzzelet Development And Technologies Ltd Compositions including cannabinoid esters
US20230066947A1 (en) * 2021-08-04 2023-03-02 Max Hammond Method for the augmentation of substance abuse therapies using cannabinoid formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2318468A1 (fr) * 1975-07-17 1977-02-11 Jaeger Dispositif electronique d'enregistrement et de lecture de donnees concernant differents parametres au cours d'un cycle predetermine, fonction de l'un desdits parametres
US5342971A (en) 1992-12-29 1994-08-30 The Australian National University Process for the preparation of dibenzo[b,d]pyrans
WO1999057107A2 (en) 1998-05-04 1999-11-11 The University Of Connecticut Cannabinoids selective for the cb2 receptor
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
US20050287180A1 (en) 2004-06-15 2005-12-29 Chen Andrew X Phospholipid compositions and methods for their preparation and use
CN102766128A (zh) 2005-09-29 2012-11-07 阿尔巴尼分子研究公司 δ-9-四氢大麻酚的生成方法
CN101384012B (zh) * 2008-10-22 2012-05-23 华为终端有限公司 系统端和终端的交互媒体文档更新方法及装置
DE102009019322A1 (de) * 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
EP2842933B1 (de) * 2013-09-03 2015-07-29 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
EP3131874B1 (en) * 2014-04-16 2018-07-25 Emerald Health Pharmaceuticals Inc. Novel cannabidiol quinone derivatives
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2531283A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
EP3061450A1 (de) 2015-02-26 2016-08-31 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
CN106810426B (zh) 2016-12-29 2020-05-08 暨明医药科技（苏州）有限公司 一种大麻二酚的合成方法
PT3509638T (pt) 2017-06-20 2022-03-02 Univ Guelph Composições de ésteres de ácido canabidiólico e suas utilizações
WO2019234728A1 (en) 2018-06-04 2019-12-12 Al&Am Pharmachem Ltd. Cannabinolic acid derivatives and uses thereof

Also Published As

Publication number Publication date
US11440870B2 (en) 2022-09-13
JP2020524679A (ja) 2020-08-20
AU2018287018B2 (en) 2022-04-28
US20200115317A1 (en) 2020-04-16
CN121534035A (zh) 2026-02-17
MX2019015311A (es) 2022-02-02
CN111032088A (zh) 2020-04-17
BR112019026916A2 (pt) 2020-06-30
DK3509638T3 (da) 2022-04-11
AU2018287018A1 (en) 2020-01-30
CA3067512A1 (en) 2018-12-27
WO2018235079A1 (en) 2018-12-27
EP3509638A1 (en) 2019-07-17
EP3509638B1 (en) 2022-01-12
PT3509638T (pt) 2022-03-02
MX389847B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
ES2909350T3 (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas
Pertwee et al. Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5‐HT1A receptor‐mediated suppression of nausea and anxiety in rats
ES2708808T3 (es) Tetrahidrocannabivarina para uso en el tratamiento de náuseas y vómitos
ES2227896T3 (es) Derivados de 1-aminometil-cicloalcanos sustituidos en 1 (=analogos de gabapentina), su preparacion y su uso en el tratamiento de trastornos neurologicos.
CN101921245B (zh) 抑制碳酸酐酶ⅱ的磺胺类化合物及合成方法与用途
ES2972711T3 (es) Tratamiento de enfermedades del CNS con estimuladores de la GCs
WO2017162108A1 (zh) 一种柱芳烃类复合物、其制备方法、药物组合物和用途
ES2549924T3 (es) Análogos de ácido araquidónico y métodos para tratamiento analgésico usando el mismo
CN109563087A (zh) sGC刺激剂的固体形式
TW200932244A (en) Methods and compositions for promoting activity of anti-cancer therapies
ES2369761T3 (es) Uso de derivados sulfamida heterocíclicos benzocondensados para el tratamiento de la obesidad.
Chen et al. Diselenium-linked dimeric prodrug nanomedicine breaking the intracellular redox balance for triple-negative breast cancer targeted therapy
CN101756957A (zh) 含有青蒿素及青蒿素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
Verma et al. A review of patents on therapeutic potential and delivery of hydroge n sulfide
Class et al. Patent application title: CANNABIDIOLIC ACID ESTERS COMPOSITIONS AND USES THEREOF Inventors: Raphael Mechoulam (Jerusalem, IL) Linda Parker (Campbell River, British Columbia, CA) Roger Pertwee (Aberdeen, Scotland, GB) Aron Weller (Shoham, IL) Joseph Tam (Jerusalem, IL) Christeen Haj (Nazareth Hit, IL) Reem Smoum (Jerusalem, IL)
CN110003142A (zh) 一种硒氰化合物及其用途
HK40028173A (en) Cannabidiolic acid esters compositions and uses thereof
CN107446010A (zh) 一种红霉素衍生物及其制备方法和应用
CN102228696B (zh) 聚乙二醇-聚乙烯醇共聚物-美他沙酮前药及其合成方法
ES2694110T3 (es) Fármaco profiláctico o terapéutico para el estreñimiento
CN105878258B (zh) 类叶升麻苷在制备抗抑郁药物中的用途
TWI463985B (zh) 單離自金剛纂之化合物於癌症和／或血小板數量低下之治療用途
CN109432079A (zh) 一种化合物在制备用于痛风的药物中的应用
CN104873493B (zh) 2‑羟基泽兰内酯在制备抗肿瘤药物中的应用
CN110003157A (zh) 一种具有抗焦虑作用的新型黄酮类化合物及其应用